Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

938
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
938
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

168
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
168
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

153
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
153
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

169
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
169
Angina IV: Management01:26

Angina IV: Management

176
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
176
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

165
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
165

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy.

Diabetes, obesity & metabolism·2024
Same author

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

European journal of heart failure·2024
Same author

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.

The lancet. Diabetes & endocrinology·2024
Same author

Biomarkers in the IL-6 Pathway and Cardiovascular Outcomes in Patients With STEMI in LATITUDE-TIMI 60.

JACC. Advances·2024
Same author

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

European journal of heart failure·2024
Same author

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.

The New England journal of medicine·2024

相关实验视频

Updated: Dec 18, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

通过皮肤冠状动脉干预后患者在P2Y抑制剂的背景下停止使用阿司匹林的安全性和有效性:系统性审查和元分析

Michelle L O'Donoghue1, Sabina A Murphy1, Marc S Sabatine1

  • 1TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.

Circulation
|June 20, 2020
PubMed
概括

在穿皮冠状动脉干预 (PCI) 后1至3个月停止服用阿司匹林,可显著降低出血风险,但不会增加重大心血管不良事件 (MACE). 这种策略对包括急性冠状动脉综合征患者在内的患者是安全的.

关键词:
抗凝固剂没有阿司匹林通过皮肤进行冠状动脉干预血小板聚合抑制剂

更多相关视频

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.1K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

相关实验视频

Last Updated: Dec 18, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.1K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

科学领域:

  • 心脏病学
  • 干预心脏病学
  • 药理学

背景情况:

  • 使用阿司匹林和P2Y12抑制剂的双重抗血小板疗法可以减少皮肤冠状动脉干预后的主要不良心血管事件 (MACE),但会增加出血风险.
  • 在PCI后停止使用阿司匹林,转而使用P2Y12抑制剂进行单一治疗的安全性和有效性仍然是临床辩论的主题.

研究的目的:

  • 评估与传统DAPT相比,在PCI后1至3个月停止使用阿司匹林,仅继续使用P2Y12抑制剂的安全性和有效性.

主要方法:

  • 进行了随机对照试验 (2001-2020) 的元分析.
  • 包括的试验比较了阿司匹林停止 (1 - 3个月PCI后) 与P2Y12抑制剂单一治疗与传统DAPT.
  • 主要结局是出血事件和MACE,随访时间为12至15个月.

主要成果:

  • 在PCI后1至3个月停用阿司匹林可显著减少40%的严重出血 (HR,0. 60),而不会增加MACE (HR,0. 88).
  • 在急性冠状动脉综合征患者中,停用阿司匹林减少了50%的出血 (HR,0.50) 并没有增加MACE (HR,0.85).
  • 在停用阿司匹林组中没有发现心肌梗塞或死亡的显著增加.

结论:

  • 在PCI后1-3个月停止使用阿司匹林,同时继续使用P2Y12抑制剂单一治疗,有效降低出血风险.
  • 这种策略似乎不会增加MACE的风险,即使是在急性冠状动脉综合征患者中.